Drug Profile

TN 201

Alternative Names: TN-201

Latest Information Update: 20 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tenaya Therapeutics
Class Cardiovascular therapies; Gene therapies
Mechanism of Action Gene transference; Myosin-binding protein C replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hypertrophic cardiomyopathy
New Molecular Entity No

Highest Development Phases

Phase I/II Hypertrophic cardiomyopathy

Most Recent Events

09 Jan 2026 Tenaya Therapeutics plans to pursue regulatory alignment on TN 201 pivotal studies over the course of 2026
12 Dec 2025 The US FDA has removes the clinical hold on the MyPEAK-1™ phase Ib/IIa trial of TN 201
10 Nov 2025 Pharmacodynamics and adverse events data from a phase I/II MyPEAK-1 trial in hypertrophic cardiomyopathy released by Tenaya Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com